These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 15221991)

  • 1. Circulating D-dimer levels are better predictors of overall survival and disease progression than carcinoembryonic antigen levels in patients with metastatic colorectal carcinoma.
    Blackwell K; Hurwitz H; Liebérman G; Novotny W; Snyder S; Dewhirst M; Greenberg C
    Cancer; 2004 Jul; 101(1):77-82. PubMed ID: 15221991
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic significance of a D-dimer cut-off level of >3 µg/ml in colorectal cancer patients treated with standard chemotherapy plus bevacizumab.
    Mochizuki S; Yoshino T; Kojima T; Fuse N; Ikematsu H; Minashi K; Yano T; Tahara M; Kaneko K; Doi T; Koike K; Ohtsu A
    Jpn J Clin Oncol; 2010 Oct; 40(10):933-7. PubMed ID: 20494948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer.
    Kabbinavar FF; Hambleton J; Mass RD; Hurwitz HI; Bergsland E; Sarkar S
    J Clin Oncol; 2005 Jun; 23(16):3706-12. PubMed ID: 15867200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. D-dimer is a marker of response to chemotherapy in patients with metastatic colorectal cancer.
    Inanc M; Er O; Karaca H; Berk V; Ozkan M; Dikilitas M; Elmali F
    J BUON; 2013; 18(2):391-7. PubMed ID: 23818351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of CA19.9 in predicting bevacizumab efficacy for metastatic colorectal cancer patients.
    Formica V; Massara MC; Portarena I; Fiaschetti V; Grenga I; Del Vecchio Blanco G; Sileri P; Tosetto L; Skoulidis F; Pallone F; Roselli M
    Cancer Biomark; 2009; 5(4):167-75. PubMed ID: 19729826
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of D-dimer correlated with disease status and poor prognosis of inoperable metastatic colorectal cancer patients treated with bevacizumab.
    Zhu L; Liu B; Zhao Y; Liu L; Yang C; Yang Y; Zhong H
    J Cancer Res Ther; 2014 Dec; 10 Suppl():246-51. PubMed ID: 25693928
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic value of plasma D-dimer levels in patients with colorectal cancer.
    Kilic M; Yoldas O; Keskek M; Ertan T; Tez M; Gocmen E; Koc M
    Colorectal Dis; 2008 Mar; 10(3):238-41. PubMed ID: 17868411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
    Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
    Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. D-dimer and international normalized ratio (INR) are correlated with tumor markers and disease stage in colorectal cancer patients.
    Kilic L; Yildiz I; Sen FK; Erdem MG; Serilmez M; Keskin S; Ciftci R; Karabulut S; Ordu C; Duranyildiz D; Tas F
    Cancer Biomark; 2015; 15(4):405-11. PubMed ID: 25792472
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen.
    Ishizuka M; Nagata H; Takagi K; Iwasaki Y; Kubota K
    Ann Surg Oncol; 2012 Oct; 19(11):3422-31. PubMed ID: 22576063
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CEA and CA19.9 as early predictors of progression in advanced/metastatic colorectal cancer patients receiving oxaliplatin-based chemotherapy and bevacizumab.
    Petrioli R; Licchetta A; Roviello G; Pascucci A; Francini E; Bargagli G; Conca R; Miano ST; Marzocca G; Francini G;
    Cancer Invest; 2012 Jan; 30(1):65-71. PubMed ID: 22236191
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of elevated D-dimer for survival in patients with sarcoma.
    Raj SD; Zhou X; Bueso-Ramos CE; Ravi V; Patel S; Benjamin RS; Vadhan-Raj S
    Am J Clin Oncol; 2012 Oct; 35(5):462-7. PubMed ID: 21654313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of immunohistochemical prognostic markers for survival after resection of pulmonary metastases from colorectal carcinoma.
    Pfannschmidt J; Bade S; Hoheisel J; Muley T; Dienemann H; Herpel E
    Thorac Cardiovasc Surg; 2009 Oct; 57(7):403-8. PubMed ID: 19795327
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circulating endothelial progenitors and CXCR4-positive circulating endothelial cells are predictive markers for bevacizumab.
    Matsusaka S; Mishima Y; Suenaga M; Terui Y; Kuniyoshi R; Mizunuma N; Hatake K
    Cancer; 2011 Sep; 117(17):4026-32. PubMed ID: 21858803
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of reverse transcriptase-polymerase chain reaction measurement of carcinoembryonic antigen mRNA levels in tumor drainage blood and peripheral blood of patients with colorectal carcinoma.
    Taniguchi T; Makino M; Suzuki K; Kaibara N
    Cancer; 2000 Sep; 89(5):970-6. PubMed ID: 10964326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Prognostic associations of preoperative plasma levels of fibrinogen and D-dimer after curative resection in patients with colorectal cancer].
    Wang JF; Guo Z; Tang L; Guo JS; Hu J; Liu JZ
    Zhonghua Yi Xue Za Zhi; 2013 Mar; 93(12):906-9. PubMed ID: 23863674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gamma-glutamyl transpeptidase level is a novel adverse prognostic indicator in human metastatic colorectal cancer.
    He WZ; Guo GF; Yin CX; Jiang C; Wang F; Qiu HJ; Chen XX; Rong RM; Zhang B; Xia LP
    Colorectal Dis; 2013 Aug; 15(8):e443-52. PubMed ID: 23621885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of clinical prognostic factors for survival and time to progression in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
    Yuste AL; Aparicio J; Segura A; López-Tendero P; Gironés R; Pérez-Fidalgo JA; Díaz R; Calderero V
    Clin Colorectal Cancer; 2003 Feb; 2(4):231-4. PubMed ID: 12620142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective cohort study of metastatic colorectal cancer patients treated with oxaliplatin-based chemotherapy, with an exploratory analysis of changing serum carcinoembryonic antigen levels.
    Ng SL; Burns WI; Snyder RD; Newnham GM; McLachlan SA; Liew D; Dowling AJ
    Asia Pac J Clin Oncol; 2012 Jun; 8(2):172-9. PubMed ID: 22524576
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.